Table 1.
Estimated postponement of death in 11 trials comparing statin therapy with no treatment or placebo
| Study ID, reference, publication year | Number included | Intervention/comparator | Prevention | Cut point, years | Dead: statin/control, % | RR (95% CI) | NNT | Postponement, days (SD) | Postponement, quick method, days |
|---|---|---|---|---|---|---|---|---|---|
| ALLHAT-LLT22 2002 | 10 355 | Pravastatin (40 mg) vs usual care | Primary | 6 | 14.9/15.3 | 0.99 (0.89 to 1.11) | 250 | −4.96 (0.06) | −5.48 |
| ASCOT-LLA23 2003 | 19 342 | Atorvastatin (10 mg) vs placebo | Primary | 3.5 | 3.6/4.1 | 0.87 (0.71 to 1.06) | 200 | 1.99 (0.04) | 1.94 |
| CARDS24 2004 | 2838 | Atorvastatin (10 mg) vs placebo | Primary | 4.8 | 4.3/5.8 | 0.73 (0.52 to 1.01) | 66.7 | 18.66 (0.04) | 17.21 |
| JUPITER25 2008 | 17 802 | Rosuvastatin (20 mg) vs placebo | Primary | 4 | 2.22/2.77 | 0.80 (0.67 to 0.97) | 31 | 7.26 (0.01) | 7.25 |
| MEGA26 2006 | 7832 | Pravastatin (5–20 mg) vs no treatment | Primary | 5 | 1.11/1.66 | 0.68 (0.46 to 1.00) | 182 | 4.42 (0.01) | 4.47 |
| WOSCOPS27 1995 | 6595 | Pravastatin (40 mg) vs placebo | Primary | 5 | 3.2/4.1 | 0.78 (0.60 to 1.00) | 111 | 9.33 (0.10) | 8.29 |
| 4S28 1994 | 4444 | Simvastatin (10–40 mg) vs placebo | Secondary | 5.8 | 8.7/12.3 | 0.7 (0.58 to 0.85) | 27.8 | 27.18 (0.26) | 31.96 |
| GISSI-HF29 2008 | 4631 | Rosuvastatin (10 mg) vs placebo | Secondary | 4.4 | 28.8/28.1 | 1.00 (0.90 to 1.12) | −143 | −9.51 (0.01) | −10.44 |
| GISSI-P14 2000 | 4271 | Pravastatin (20 mg) vs no treatment | Secondary | 2.0 | 3.37/4.13 | 0.84 (0.61 to 1.14) | 132 | 1.76 (0.07) | 2.53 |
| LIPID30 1998 | 9014 | Pravastatin (40 mg) vs placebo | Secondary | 6.1 | 11.0/14.1 | 0.78 (0.69 to 0.87) | 32.3 | 22.05 (0.21) | 26.59 |
| CORONA13 2007 | 5011 | Rosuvastatin (10 mg) vs placebo | Secondary | 2.7 | 29.0/30.4 | 0.95 (0.86 to 1.05) | 71 | 4.09 (0.04) | 4.16 |
NNT, number needed to treat; RR, relative risk.